Halozyme Therapeutics (HALO) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-75.64M
Share-based compensation	18.84M
Depreciation and amortization	1.77M
(Gain) loss on disposal of equipment
Accounts receivable	14.73M
Inventory	-3.36M
Prepaid expenses and other assets	1.09M
Accounts payable and accrued expenses	-1.4M
Deferred rent
Deferred revenue	-2.48M
Net cash used in operating activities
Purchases of property and equipment	-2.69M
Net cash used in investing activities
Proceeds from exercise of stock options, net
Net cash provided by financing activities
Net decrease in cash and cash equivalents	17.92M
Cash and cash equivalents at beginning of period	43.29M
Cash and cash equivalents at end of period	61.21M
Accounts payable for purchases of property and equipment

Entities mentioned with halo

View All Entities